Search Results - "DARTOIS, Céline"

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging by Schnell, Christian R, Stauffer, Frédéric, Allegrini, Peter R, O'Reilly, Terence, McSheehy, Paul M J, Dartois, Celine, Stumm, Michael, Cozens, Robert, Littlewood-Evans, Amanda, García-Echeverría, Carlos, Maira, Sauveur-Michel

“…Dysregulated angiogenesis and high tumor vasculature permeability, two vascular endothelial growth factor (VEGF)-mediated processes and hallmarks of human…”
Get full text

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004 by BRENDEL, Karl, DARTOIS, Céline, COMETS, Emmanuelle, LEMENUEL-DIOT, Annabelle, LAVEILLE, Christian, TRANCHAND, Brigitte, GIRARD, Pascal, LAFFONT, Céline M, MENTRD, France

“…Model evaluation is an important issue in population analyses. We aimed to perform a systematic review of all population pharmacokinetic and/or pharmacodynamic…”
Get full text

Evaluation of uncertainty parameters estimated by different population PK software and methods by Dartois, Céline, Lemenuel-Diot, Annabelle, Laveille, Christian, Tranchand, Brigitte, Tod, Michel, Girard, Pascal

“…The uncertainty associated with parameter estimations is essential for population model building, evaluation, and simulation. Summarized by the standard error…”
Get full text

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease by DARTOIS, Céline, FREYER, Gilles, MICHALLET, Mauricette, HENIN, Emilie, YOU, Benoit, DARLAVOIX, Isabelle, VERMOT-DESROCHES, Claudine, TRANCHAND, Brigitte, GIRARD, Pascal

“…Inolimomab, a monoclonal antibody against interleukin (IL)-2Ralpha (CD25) has shown promising results in the treatment of corticosteroid-resistant acute…”
Get full text

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey by Dartois, C., Brendel, K., Comets, E., Laffont, C. M., Laveille, C., Tranchand, B., Mentré, F., Lemenuel‐Diot, A., Girard, P.

“…What is already known about this subject • The reviews already published on population pharmacokinetic/pharmacodynamic (PK/PD) analyses have focused on theory…”
Get full text

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease: Exposure-Effect population model of inolimomab by Dartois, Céline, Freyer, Gilles, Michallet, Mauricette, Hénin, Emilie, You, Benoît, Darlavoix, Isabelle, Vermot-Desroches, Claudine, Tranchand, Brigitte, Girard, Pascal

“…BACKGROUND AND OBJECTIVE: Inolimomab, a monoclonal antibody against interleukin (IL)-2Ralpha (CD25) has shown promising results in the treatment of…”
Get full text

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004: Are population PK/PD models adequately evaluated? by Brendel, Karl, Dartois, Céline, Comets, Emmanuelle, Lemenuel-Diot, Annabelle, Laveille, Christian, Tranchand, Brigitte, Girard, Pascal, Laffont, Céline M., Mentré, France

“…Model evaluation is an important issue in population analyses. We aimed to perform a systematic review of all population pharmacokinetic and/or pharmacodynamic…”
Get full text